Divi's Laboratories has said that its Unit-I at Choutuppal, Telangana, has had undergone USFDA inspection between May 14-16, 2018. This was a routine cGMP inspection by the US health regulator. The inspection has been concluded with 483 observations.
Divi’s Lab is in the process of building two additional production blocks at this facility; hence, from a growth perspective, this is an important unit.
Divi’s Laboratories is a research-focused contract manufacturing player (bulk drugs/intermediates). The company undertakes custom manufacturing of APIs and production of advanced intermediates, thus offering a competitive advantage to its clients over the entire life cycle of the products.
Divis Laboratories Ltd ended the day at Rs1,169.10, up Rs20.2, or 1.76%, from its previous close of Rs1,148.90 on the BSE.
The scrip opened at Rs1,163.80 and has touched a high and low of Rs1,170 and Rs1,140, respectively. So far, 6,59,459 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs30,499.69cr.